

Investor Webinar – Wed 5 March @ 2pm AEDT

Nova Eye Medical Limited (ASX: EYE) (Nova Eye Medical or the Company), a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to invite shareholders and interested parties to an Investor Webinar on **Wednesday, 5 March 2025, at 2pm AEDT**.

Managing Director Tom Spurling will discuss Nova Eye Medical's recently released Half-Yearly financial results and accompanying Investor Presentation, "*Selling highly effective products that eye surgeons want into a market that is large and growing*".

Webinar Details

- **Date: Wednesday, 5 March 2025**
- **Time: 2pm AEDT**
- **Presenter: Tom Spurling, Nova Eye Medical Managing Director**
- **Registration Link: <https://bit.ly/43hZxAy>**

Participants will have the opportunity to submit questions before the webinar by emailing mflynn@nova-eye.com or during the live Q&A session.

The Company encourages investors to attend this session to gain further insights into the Company's financial results which show strong sales growth with the Glaucoma Division on track for profitability as well as its strategy to continue growing the Company's sales and markets.

Authorised for lodgement by the Board of Directors of Nova Eye Medical Limited.

-ends-

For more information:

Company

Tom Spurling
Managing Director
+61 417 818 658
tspurling@nova-eye.com

Investors

Mark Flynn
Investor Relations
+61 416 068 733
mflynn@nova-eye.com

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack™ Advance, a minimally invasive consumable glaucoma surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com